Lundbeck
Update in progressHLUN-B.CO (Copenhagen)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
H. Lundbeck A/S researches, develops, manufactures and markets medicines for psychiatric and neurological disorders worldwide. Its portfolio includes Abilify Maintena/Abilify Asimtufii for schizophrenia and bipolar I, Brintellix/Trintellix for depression, Rexulti/Rxulti for MDD and schizophrenia, Vyepti for migraine prevention, Cipralex/Lexapro for depression, Northera for neurogenic orthostatic hypotension, Onfi for epilepsy, Ebixa for dementia, Azilect for Parkinson’s, and Xenazine for chorea, plus several pipeline programs. Founded 1915, based in Valby, Denmark.
Company score
- Sentiment
- 0.13
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.09
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!